Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-18 pm EDT			After market 07:08:03 pm
145.7 ^USD	+0.67%		145.4	-0.26%

12:33am	US FDA mandates label updates on CAR-T cancer therapies	RE
Apr. 18	Medical device maker Intuitive beats estimates on strong demand for surgical robots	RE

Johnson & Johnson : to Participate in Bernstein's 35th Annual Strategic Decisions Conference

May 17, 2019 at 08:54 am EDT

NEW BRUNSWICK, N.J., May 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in Bernstein's 35^th Annual Strategic Decisions Conference on Thursday, May 30, at the Grand Hyatt, New York. Alex Gorsky, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 12:00 p.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately two hours after the live webcast.

(PRNewsfoto/Johnson & Johnson)

View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-bernsteins-35th-annual-strategic-decisions-conference-300852402.html

SOURCE Johnson & Johnson

Latest news about Johnson & Johnson

US FDA mandates label updates on CAR-T cancer therapies	06:33pm	RE
Medical device maker Intuitive beats estimates on strong demand for surgical robots	Apr. 18	RE
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
Johnson & Johnson's Q1 Had 'Some Puts and Takes,' Morgan Stanley Says	Apr. 17	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
US stocks see-saw as rising Treasury yields, Middle East tensions cap gains	Apr. 16	RE
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	Apr. 16	MT
Wall Street stocks mixed on higher Treasury yields, rate expectations	Apr. 16	RE
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Correction to Johnson & Johnson Earnings Article	Apr. 16	DJ
Top Midday Stories: UnitedHealth, Johnson & Johnson, Bank of America, Morgan Stanley, PNC, Bank of New York Mellon, Northern Trust and Ericsson Report Q1 Earnings; AMD Launches New Processors; Meta's Zuckerberg Wins Case Dismissal; Planet Fitness Names New CEO	Apr. 16	MT
S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow	Apr. 16	RE
Trending : Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend	Apr. 16	DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Apr. 16	MT
Market sentiment sours	Apr. 16
Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views	Apr. 16	MT
Wall St set for higher open as upbeat earnings obscure Mideast jitters	Apr. 16	RE
Transcript : Johnson & Johnson, Q1 2024 Earnings Call, Apr 16, 2024	Apr. 16

Chart Johnson & Johnson

Duration

Period

More charts

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Annual General Meeting

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST

More Strategies

Ratings for Johnson & Johnson

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

145.7 USD

Average target price

172.5 USD

Spread / Average Target

+18.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOHNSON & JOHNSON	-7.02%	351B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.58%	550B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.96%	211B
NOVARTIS AG	-0.41%	203B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B
AMGEN INC.	-8.80%	141B

Other Pharmaceuticals

Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Johnson & Johnson : to Participate in Bernstein's 35th Annual Strategic Decisions Conference

EPS Revisions